Clinical trials: Advanced Solid Malignant Tumor
Advanced Solid Tumor
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.
- Trial name
- NCT07110883
- Testing
- SYS6023
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Breast Cancer, Colon Cancer
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor.
- Conditions
- Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
- Trial name
- NCT01068483
- Testing
- BKM120
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a single agent in adult subjects with…
- Trial name
- NCT04547205
- Testing
- AK109
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Advanced Solid Malignancies
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid malignancies.This study consists of 2 cohorts.
- Trial name
- NCT03736473
- Testing
- MEDI9447 (oleclumab)
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects
- Trial name
- NCT06529445
- Testing
- High Dose VC004 Capsules, Median Dose VC004 Capsules, Low Dose VC004 Capsules
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Advanced Solid Tumors
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
- Trial name
- NCT01255657
- Testing
- ABT-806
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Advanced Malignant Solid Tumors
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs…
- Trial name
- NCT00958724
- Testing
- Neratinib, Vinorelbine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Puma Biotechnology, Inc.
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Advanced Solid Tumor
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
- Trial name
- NCT04973020
- Testing
- SHR6390、efavirenz
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
A Study of ASP2074 in Adults With Solid Tumors
ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body.
- Trial name
- NCT05646797
- Testing
- ASP2074
- Where
- 13 sites in United States, Japan
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841.
- Trial name
- NCT06352359
- Testing
- ONC-841
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- OncoC4, Inc.
Advanced Solid Tumor, PIK3CA Mutation
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side…
- Conditions
- Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
- Trial name
- NCT05300048
- Testing
- Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Faeth Therapeutics
Advanced Solid Tumor
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
- Trial name
- NCT05354843
- Testing
- ET0038
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
Carcinoma
ARQ 501 in Combination With Docetaxel in Patients With Cancer
The purpose of this study is to determine the safety of ARQ 501 in combination with docetaxel in patients with advanced or metastatic cancer.
- Trial name
- NCT00099190
- Testing
- ARQ 501
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor
- Trial name
- NCT05650580
- Testing
- TR115
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tarapeutics Science Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.